HR+ BREAST CANCER
Clinical trials for HR+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+ BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug combo aims to shrink tumors before surgery, spare patients harsh chemo
Disease control Not yet recruitingThis study is testing a new combination of two targeted drugs, SHR-A1811 and pertuzumab, given before surgery for a specific type of breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The goal is to see if this approach can effectively shrink or elimina…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Apr 02, 2026 02:41 UTC
-
New drug targets gene flaw in Tough-to-Treat cancers
Disease control Not yet recruitingThis study is testing an investigational drug called SC-101 for people with advanced breast cancer and other solid tumors that have a specific genetic feature called NECTIN4 amplification. About 120 participants whose cancer has progressed after standard treatments will receive w…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Could CBD ease debilitating joint pain for breast cancer survivors?
Symptom relief Not yet recruitingThis study aims to see if a cannabidiol (CBD) oral solution can safely reduce joint pain and stiffness caused by standard hormone therapy in people with early-stage breast cancer. About 130 participants will take either the CBD solution or a placebo for a period, then switch, to …
Matched conditions: HR+ BREAST CANCER
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Apr 02, 2026 02:42 UTC